Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.50
Bid: 297.50
Ask: 300.00
Change: -6.00 (-1.98%)
Spread: 2.50 (0.84%)
Open: 313.00
High: 313.50
Low: 296.50
Prev. Close: 302.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 8 - Oxford BioMedica PLC

24 Jan 2005 11:45

Sputnik Group Limited24 January 2005 Date of Disclosure JANUARY 24, 2005 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE CITY CODE ON TAKEOVERS AND MERGERS Date of dealing 21, 2005 Dealing in OXFORD BIOMEDICA PLC (name of company) 1) Class of securities (eg ordinary shares) ORDINARY SHARES 2) Amount bought Amount sold Price per unit 83,333 0.221100 GBP 3) Resultant total of the same class owned or controlled (and percentage of class) 3,900,001 (1.0535%) 4) Party making disclosure SPUTNIK GROUP LTD 5) EITHER (a) Name of purchaser/vendor (Note 1) SPUTNIK GROUP LTD OR (b) if dealing for discretionary client(s), name of fund management organisation 6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) NO (ii) offeree company NO Specify which category or categories of associate (1-8 overleaf) If category (8), explain (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of the class of relevant securities dealt in) YES Signed, for and on behalf of the party named in (4) above N/A (Also print name of signatory) PETER CLATEMAN Telephone and extension number +7 095 725 5019 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, eg where an owner normally acts on instructions of a controller Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or which an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Note 6 on Rule 8 Note 5. It may be necessary, particularly when disclosing derivative transactions, to append a sheet to this disclosure form so that relevant information can be given. Note 6. In the case of an average price bargain, each underlying trade should be disclosed. Note 7. The resultant total percentage holding of the class of relevant security is to be calculated by reference to the percentage held and in issue outside treasury. For full details of disclosure requirements, see Rule 8 of the Code. If in doubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No:020 7638 0129. Email: monitoring@disclosure.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Jul 20227:00 amRNSExpanded Agreement with BMS’s Juno in CAR-T
15th Jul 202210:13 amRNSBLOCK LISTING RETURN
1st Jul 20229:55 amRNSTotal Voting Rights
1st Jul 20227:00 amRNSSigns new agreement with AstraZeneca
14th Jun 20227:00 amRNSNotes FDA lift clinical hold on pheNIX trial
1st Jun 20227:00 amRNSTotal Voting Rights
27th May 20226:03 pmRNSResult of AGM
3rd May 20225:18 pmRNSGrant of options
3rd May 20224:46 pmRNSDirector/PDMR Shareholding
3rd May 202210:35 amRNSTotal Voting Rights
29th Apr 20225:42 pmRNSDirectors Dealings / Market Share Purchases
28th Apr 20222:24 pmRNSDirector/PDMR Shareholding
27th Apr 20222:58 pmRNS2021 Annual report and accounts & AGM notification
27th Apr 202212:10 pmRNSPDMR Dealings / Market Share Purchase
21st Apr 20224:41 pmRNSDirector Share Purchase
21st Apr 20221:24 pmRNSDirectors Dealings / Market Share Purchase
21st Apr 202210:16 amRNSDirector/PDMR Shareholding
20th Apr 20223:45 pmRNSDirector/PDMR Shareholding
20th Apr 20227:00 amRNSPreliminary Results
13th Apr 20227:00 amRNSBoard Appointment
4th Apr 202211:34 amRNSNotice of Preliminary Results
1st Apr 20226:30 pmRNSHolding(s) in Company
1st Apr 202210:33 amRNSBlock listing Application
1st Apr 20229:34 amRNSTotal Voting Rights
31st Mar 20226:07 pmRNSHolding(s) in Company
30th Mar 20221:00 pmRNSHolding(s) in Company
25th Mar 20225:15 pmRNSHolding(s) in Company
21st Mar 202210:44 amRNSLong Term Incentive Plan Option Grant
15th Mar 202211:25 amRNSHolding(s) in Company
15th Mar 20229:39 amRNSHolding(s) in Company
11th Mar 20224:51 pmRNSHolding(s) in Company
11th Mar 20229:01 amRNSAdmission of Conditional Placing Shares
10th Mar 20225:32 pmRNSCompletion of Transaction
9th Mar 202211:42 amRNSDirector Declaration
8th Mar 20223:54 pmRNSResult of General Meeting
1st Mar 20229:52 amRNSTotal Voting Rights
16th Feb 202211:41 amRNSPublication of Circular & Notice of GM
4th Feb 20228:22 amRNSAdmission of Firm Placing Shares
1st Feb 20229:06 amRNSTotal Voting Rights
1st Feb 20227:00 amRNSUpdate to agreement with Sio Gene Therapies
31st Jan 202211:21 amRNSMarket Share Purchase
28th Jan 20225:59 pmRNSResult of Placing and PrimaryBid offer
28th Jan 20222:04 pmRNSHoldings in Company
28th Jan 20227:38 amRNSRetail offer by PrimaryBid
28th Jan 20227:24 amRNSUS Agreement and Proposed Placing of Shares
17th Jan 20227:00 amRNSJohn Dawson to retire from Oxford Biomedica
5th Jan 20227:00 amRNSOxford Biomedica Agreement with Cabaletta Bio
4th Jan 202211:07 amRNSBlock listing Return
4th Jan 202210:32 amRNSTotal Voting Rights
4th Jan 20227:00 amRNSJohn Dawson awarded CBE in New Year Honours List

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.